Stent showdown: which Drug-Coated device keeps heart arteries open longer?
NCT ID NCT00960648
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at over 3000 people with coronary artery disease to compare two types of drug-eluting stents: everolimus-eluting (Xience/Promus) and sirolimus-eluting (Cypher). The goal was to see which one better prevents major heart problems like heart attacks or the need for repeat procedures. Researchers tracked patients for several years to measure safety and long-term effectiveness in real-world use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
drug-eluting stents (everolimus-eluting stent and sirolimus-eluting stent)
What this could lead to
If successful, this could confirm that everolimus-eluting stents are as safe and effective as sirolimus-eluting stents for treating blocked heart arteries.
What could go wrong
This is a completed registry study, not a randomized trial, so results may be less definitive. Stents carry risks like blood clots or re-narrowing of the artery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chonbuk National University Hospital
Iksan, South Korea
-
Chungbuk National University Hospital
Cheongju-si, South Korea
-
Dankook University Hospital
Cheonan, South Korea
-
Gachon Kil Medical Center
Inchon, South Korea
-
Gangnam Severance Hospital
Seoul, South Korea
-
Gyeongsang National University Hospital
Jinju, South Korea
-
Inje University Ilsan Paik Hospital
Ilsan, South Korea
-
Inje University Pusan Paik Hospital
Pusan, South Korea
-
Kwangju Veterans Hospital
Gwangju, South Korea
-
Kyung Hee University Medical Center
Seoul, South Korea
-
Presbyterian Medical Center
Jeonju, South Korea
-
Samsung Medical Center
Seoul, South Korea
-
Seoul National University Bundang Hospital
Seongnam, South Korea
-
Seoul National University Hospital
Seoul, South Korea
-
Soon Chun Hyang University Hospital Cheonan
Cheonan, South Korea
-
St. Carollo Hospital
Suncheon, South Korea
-
Wonkwang University Hospital
Iksan, South Korea
-
Yonsei University Medical Center
Seoul, South Korea